Abstract ID: 191 for Conference for Undergraduate Research at FIU (Auto-Generated August 29, 2017 1:03 pm)

Ethics of Cystic Fibrosis Gene Therapies

by

Michelle Rojas
Abstract Id: 191 Submitted: February 27, 2017 Event: Conference for Undergraduate Research at FIU
2017 Topic: Microbiology & Immunology

While knowledge of genetics originated centuries ago, the field had difficulty progressing
until the Human Genome Project (HGP) expanded this topic of study by offering new insights on
human genetics. The HGP was created to organize and lay out the complete set of genetic material
in a species otherwise known as the genome, this project also aided in the discovery of diseasecausing genes. The recognition of disease-causing genes led to the formulation of gene therapies to
treat specific disorders such as cystic fibrosis. This study analyzes not only how ethics are impacting
the development of cystic fibrosis gene therapies but also exhibits how scientist view ethical
concerns on these treatments and their beliefs. It also demonstrates a deeper connection to the
awareness of ethical concerns in the scientific community because even though some of the ethical
issues are common knowledge they are not deeply analyzed by individuals in the science field. The
study was conducted by interviewing professionals in the Science filed focused on working with
cystic fibrosis. The results of the experiment show a hindering in the development of cystic fibrosis
gene therapies, this is due to the ethical issue causing limitations in the research process. Ethics has
played a role in the development of cystic fibrosis gene therapies considering that this research
began in the 1990’s. The development of new technology urges the scientific community to deal with
societal concerns about this research in order to bring these treatments to the public and improve
the patients’ quality of life.
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